Zacks Investment Research on MSN6h
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its ...
ConsumerAffairs9h
FDA greenlights new drug to treat a serious type of heart disease
Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...
Healio7h
FDA approves vutrisiran for ATTR amyloidosis with cardiomyopathy
Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...
Managed Healthcare Executive3h
FDA Approves Amvuttra for ATTR-CM in Extended Label
This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...
Investor's Business Daily on MSN3h
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.
TCTMD7h
Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM
Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...
Medscape8h
FDA Expands Vutrisiran Indication to ATTR-Cardiomyopathy
The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary transthyretin-mediated amyloidosis.
BioPharma Dive7h
Alnylam prices heart drug at premium to rivals
Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.
MPR4h
Amvuttra Gains Approval for Transthyretin Amyloid Cardiomyopathy
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps
The approval expands the indication for Amvuttra, which now becomes the first and only therapeutic approved by the FDA for ...
Alnylam’s Amvuttra approved by FDA in cardiomyopathy
Alnylam (ALNY) announced the FDA approval of the supplemental New Drug Application for its RNAi therapeutic, Amvuttra, for the treatment of the ...